Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCMA CAR-T Therapy for Relapsed/Refractory Multiple Myeloma
NCT05430945Phase 1Unknown
- Sponsor
- Zhejiang University
- Start
- Jun 2022
- Primary completion
- Jun 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BCMA targeted CAR T-cells in multiple myeloma (MM), sponsored by Zhejiang University. Primary endpoints: Dose-limiting toxicity at 28 days and Treatment-emergent adverse events at 2 years. Status: unknown.
02
Drugs
BCMA targeted CAR T-cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05430945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05430945.